BioSapien is a technology company.
BioSapien has raised $10.0M across 2 funding rounds.
BioSapien has raised $10.0M in total across 2 funding rounds.
BioSapien has raised $10.0M in total across 2 funding rounds.
BioSapien's investors include Global Ventures, SOSV, Breakthrough Energy Ventures, Darco Capital, Northpond Ventures, Tet Ventures, Mark Cuban.
BioSapien is a late-stage preclinical biotech company founded in 2018, specializing in minimally invasive drug delivery platforms for cancer treatment.[1][2] Its flagship product, MediChip™, is a 3D-printed biocompatible patch that delivers targeted chemotherapy directly to tumors, reducing systemic side effects like nausea and fatigue while enabling sustained local dosing for lower gastrointestinal and solid tumors.[1][2][3][5] Serving oncologists, surgeons, and patients with inoperable or hard-to-treat cancers, MediChip addresses the limitations of systemic chemotherapy by shrinking tumors, easing symptoms, and potentially enabling surgery—backed by $9.06M in total funding, including a recent $5.5M pre-Series A round to launch UAE clinical trials in Q2 2025.[1][3]
The company demonstrates strong growth momentum: global patents issued in 2023 across multiple regions (expiring 2039), acceptance into accelerators like HUB71, and partnerships with Abu Dhabi hospitals, positioning it for rapid clinical advancement in a $247B global cancer drug delivery market.[2][3][4][5]
BioSapien was founded in 2018 in San Diego, California, by Dr. Khatija Ali, a visionary leader driven by a personal question: "Shouldn’t fighting cancer be about regaining control, not losing it?"[2][3][4] Ali, leveraging over 100 years of combined team expertise from academia, medicine, and engineering, developed MediChip™ to revolutionize localized cancer therapy.[2]
The idea emerged from frustration with systemic chemo's harsh side effects and uneven tumor response, leading to pre-seed funding of $250K in 2019 from friends, family, RebelBio, and IndieBio.[2] Pivotal moments include regulatory approvals in 2022, global patent issuances in 2023, and funding escalations—reaching $3M by 2024 and $9.06M overall with recent rounds like $1.8M and $5.5M pre-Series A led by Global Ventures.[1][2][3][5] These milestones fueled progression to late-stage preclinical status and UAE trial preparations.[3]
BioSapien rides the wave of precision oncology and localized drug delivery, fueled by rising cancer incidence, demand for personalized medicine, and 3D printing's maturation in pharma (e.g., competitors like Triastek).[1][4] Timing aligns with post-2020 surges in cancer care spending ($208.9B in US alone) and MENA's biotech push—UAE's oncology focus, genetic diversity, and infrastructure enable BioSapien's trials and scaling.[3][4][5]
Market forces favor it: $247B global cancer drug delivery sector (colorectal subset at $19B+), unmet needs in minimally invasive options amid chemo resistance and surgery limitations.[3] BioSapien influences the ecosystem by pioneering MENA biotech innovation, partnering with top hospitals, and demonstrating scalability beyond cancer—potentially disrupting $246B+ markets while lowering healthcare costs.[2][4]
BioSapien is primed for breakout with Q2 2025 UAE trials, manufacturing expansion, and talent growth, targeting 1M patients by 2035 via MediChip's adaptable platform.[2][3] Trends like AI-driven personalization, 3D bioprinting, and global oncology investments will accelerate its path to Series A and multi-tumor approvals, evolving from San Diego startup to global leader in patient-empowering biotech.[1][4]
This positions BioSapien to transform cancer from a systemic battle into a targeted victory—fulfilling its mission to advance human well-being through innovation that reclaims control for patients.[2]
BioSapien has raised $10.0M across 2 funding rounds. Most recently, it raised $8.0M Seed in December 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 1, 2024 | $8.0M Seed | Global Ventures, SOSV | |
| Nov 1, 2021 | $2.0M Seed | Breakthrough Energy Ventures, Darco Capital, Northpond Ventures, SOSV, Tet Ventures, Mark Cuban |